pharma · TTR-mediated Amyloidosis · Hypertension · ALNY
Alnylam Netherlands
Alnylam Netherlands B.V.
Alnylam Netherlands is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker ALNY. Primary therapeutic focus areas include TTR-mediated Amyloidosis, Hypertension, Transthyretin Amyloidosis
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2002
- Employees
- 2,826
- Programs
- 84
- Drugs
- 37
- Patents
- 379
Mivelsiran, Placebo
Phase 2 · small molecule · Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain
Mivelsiran, Placebo for Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain is a Phase 2 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code ALN-APP-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alnylam Netherlands B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain
- Status
- active
- Trials
- 1